{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:40:09Z","timestamp":1786372809719,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,1]]},"abstract":"\n Background and objectives<\/jats:title>\n Niacin downregulates intestinal sodium-dependent phosphate transporter 2b expression and reduces intestinal phosphate transport. Short-term studies have suggested that niacin lowers serum phosphate concentrations in patients with CKD and ESRD. However, the long-term effects of niacin on serum phosphate and other mineral markers are unknown.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n \n The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglycerides: Impact on Global Health Trial was a randomized, double-blind, placebo-controlled trial testing extended release niacin in persons with prevalent cardiovascular disease. We examined the effect of randomized treatment with niacin (1500 or 2000 mg) or placebo on temporal changes in markers of mineral metabolism in 352 participants with eGFR<60 ml\/min per 1.73 m\n 2<\/jats:sup>\n over 3 years. Changes in each marker were compared over time between the niacin and placebo arms using linear mixed effects models.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Randomization to niacin led to 0.08 mg\/dl lower plasma phosphate concentrations per year of treatment compared with placebo (\n P<\/jats:italic>\n <0.01) and 0.25 mg\/dl lower mean phosphate 3 years after baseline (3.32 versus 3.57 mg\/dl;\n P<\/jats:italic>\n =0.03). In contrast, randomization to niacin was not associated with statistically significant changes in plasma intact fibroblast growth factor 23, parathyroid hormone, calcium, or vitamin D metabolites over 3 years.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The use of niacin over 3 years lowered serum phosphorous concentrations but did not affect other markers of mineral metabolism in participants with CKD.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.05440517","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T20:35:16Z","timestamp":1512506116000},"page":"36-44","source":"Crossref","is-referenced-by-count":33,"title":["The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD"],"prefix":"10.2215","volume":"13","author":[{"given":"Rakesh","family":"Malhotra","sequence":"first","affiliation":[{"name":"Division of Nephrology-Hypertension, Department of Medicine and"},{"name":"Imperial Valley Family Care Medical Group, El Centro, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Katz","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hoofnagle","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bostom","sequence":"additional","affiliation":[{"name":"Division of Hypertension and Kidney Diseases, Rhode Island Hospital, Providence, Rhode Island;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena E.","family":"Rifkin","sequence":"additional","affiliation":[{"name":"Division of Nephrology-Hypertension, Department of Medicine and"},{"name":"Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California, San Diego, California;"},{"name":"Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Mcbride","sequence":"additional","affiliation":[{"name":"Axio Research, Seattle, Washington; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Probstfield","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Block","sequence":"additional","affiliation":[{"name":"Denver Nephrology, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim H.","family":"Ix","sequence":"additional","affiliation":[{"name":"Division of Nephrology-Hypertension, Department of Medicine and"},{"name":"Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California, San Diego, California;"},{"name":"Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,12,5]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"473","DOI":"10.7326\/M16-0273","article-title":"Trends in prevalence of chronic kidney disease in the United States.","volume":"165","author":"Murphy","year":"2016","journal-title":"Ann Intern Med"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/ki.2012.39","article-title":"The contribution of chronic kidney disease to the global burden of major noncommunicable diseases.","volume":"81","author":"Woo","year":"2012","journal-title":"Kidney Int"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification.","volume":"87","author":"Jono","year":"2000","journal-title":"Circ Res"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000346784","article-title":"Phosphate toxicity and vascular mineralization.","volume":"180","author":"Razzaque","year":"2013","journal-title":"Contrib Nephrol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1681\/ASN.2008040349","article-title":"Association of serum phosphate with vascular and valvular calcification in moderate CKD.","volume":"20","author":"Adeney","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1681\/ASN.2006121385","article-title":"Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice.","volume":"18","author":"Stubbs","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1681\/ASN.V9101845","article-title":"High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro.","volume":"9","author":"Almaden","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways.","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol Rev"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"B10-20230813","article-title":"KDOQI US Commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) [published online ahead of print September 20, 2017].","author":"Isakova","journal-title":"Am J Kidney Dis"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD.","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2215\/CJN.05170513","article-title":"Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.","volume":"9","author":"Yokoyama","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/ndt\/gfq419","article-title":"Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.","volume":"26","author":"Isakova","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","article-title":"Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients.","volume":"26","author":"Gonzalez-Parra","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia.","volume":"28","author":"Fishbane","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.","volume":"3","author":"Cheng","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MNH.0000000000000236","article-title":"Nicotinamide and phosphate homeostasis in chronic kidney disease.","volume":"25","author":"Ginsberg","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/ndt\/14.5.1195","article-title":"Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine.","volume":"14","author":"Katai","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"B19-20230813","first-page":"F15","article-title":"Nicotinamide as a rapid-acting inhibitor of renal brush-border phosphate transport.","volume":"255","author":"Wu","year":"1988","journal-title":"Am J Physiol"},{"key":"B20-20230813","first-page":"963","article-title":"Sustained hypophosphatemic effect of once-daily niacin\/laropiprant in dyslipidemic CKD stage 3 patients.","volume":"57","author":"Ix","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1373\/clinchem.2010.161174","article-title":"Quantification of 1\u03b1,25-dihydroxy vitamin D by immunoextraction and liquid chromatography-tandem mass spectrometry.","volume":"57","author":"Strathmann","year":"2011","journal-title":"Clin Chem"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1515\/CCLM.2010.318","article-title":"First certified reference material for cystatin C in human serum ERM-DA471\/IFCC.","volume":"48","author":"Grubb","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C.","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ndt\/gfx249","article-title":"Efficacy and safety of nicotinamide in haemodialysis patients: The NICOREN study.","volume":"32","author":"Lenglet","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000362424","article-title":"Effect of niacin on FGF23 concentration in chronic kidney disease.","volume":"39","author":"Rao","year":"2014","journal-title":"Am J Nephrol"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.13281211","article-title":"Fibroblast growth factor 23 and Inflammation in CKD.","volume":"7","author":"Munoz Mendoza","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2013.12.001","article-title":"Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.","volume":"60","author":"Imel","year":"2014","journal-title":"Bone"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2011.06.011","article-title":"Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: The Heart and Soul study.","volume":"58","author":"Ix","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/jbmr.65","article-title":"Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice.","volume":"25","author":"Tsuji","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1681\/ASN.2016080855","article-title":"Effect of tenapanor on serum phosphate in patients receiving hemodialysis.","volume":"28","author":"Block","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/ki.2014.383","article-title":"Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: A post hoc analysis of the AIM-HIGH trial.","volume":"87","author":"Kalil","year":"2015","journal-title":"Kidney Int"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1681\/ASN.2015020117","article-title":"Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD.","volume":"26","author":"Isakova","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3945\/ajcn.114.085498","article-title":"Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: A crossover study.","volume":"100","author":"Ix","year":"2014","journal-title":"Am J Clin Nutr"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201801000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:27Z","timestamp":1786369047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201801000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,5]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.05440517","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,5]]}}}